Back to results
US 12,312,417 B2Granted
Binding proteins 1
AssigneesNucleus Therapeutics Pty. Ltd, Yale University
InventorsJames Campbell, Valentina Dubljevic, James Hansen, Zahra Rattray, Jiangbing Zhou
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to cell penetrating anti-DNA binding proteins. Compositions comprising these binding proteins may be may be useful for delivering agents to cells and treating diseases such as cancer.
Claims20
A cell penetrating antibody that binds to DNA, wherein the antibody comprises:
- a heavy chain variable region (VH) comprising:
- a complementarity determining region (CDR) 1 comprising the sequence NYGMH (SEQ ID NO:
- 1),
- a CDR2 comprising the sequence YISSGSSTIYYADSVKG (SEQ ID NO:
- 3), and
- a CDR3 comprising the sequence RGLLLDY (SEQ ID NO:
- 4);
- and
- a light chain variable region (VL) comprising:
- a CDR1 comprising the sequence RASKTVSTSSYSYMH (SEQ ID NO:
- 6),
- a CDR2 comprising the sequence YASYLES (SEQ ID NO:
- 7), and
- a CDR3 comprising the sequence QHSREFPWT (SEQ ID NO:
- 8),
- wherein the antibody is conjugated to a therapeutic compound.
13 more elements
A cell penetrating antibody that binds to DNA, wherein the antibody comprises:
- a heavy chain variable region (VH) comprising:
- a complementarity determining region (CDR) 1 comprising the sequence NYGMH (SEQ ID NO:
- 1),
- a CDR2 comprising the sequence YISSGSSTIYYADSVKG (SEQ ID NO:
- 3), and
- a CDR3 comprising the sequence RGLLLDY (SEQ ID NO:
- 4);
- and
- a light chain variable region (VL) comprising:
- a CDR1 comprising the sequence RASKTVSTSSYSYMH (SEQ ID NO:
- 6),
- a CDR2 comprising the sequence YASYLES (SEQ ID NO:
- 7), and
- a CDR3 comprising the sequence QHSREFPWT (SEQ ID NO:
- 8),
- wherein the antibody is conjugated to a nucleic acid.
13 more elements
Dependencies are inferred from the claim text.